Xiidra
About Xiidra
Xiidra is a Healthcare company founded in 2013, and was acquired by Bausch & Lomb in June 2023. Xiidra is marketed by Bausch Lomb for dry eye treatment. It operates on a Direct-to-Consumer (D2C) model. Its website xiidra.com draws about 45 thousand monthly visits. Xiidra offers products and services including Xiidra. Its focus areas include Pharmaceuticals and Ophthalmic Drugs. Its legal entity is Bausch + Lomb.
Company details
Xiidra, managed by Bausch Lomb, is focused on providing prescription eye drops for treating signs and symptoms of dry eye disease. The product is developed to address inflammation, a root cause of dry eye, offering relief in as little as two weeks with continued use. It is distributed across the United States with extensive insurance coverage for both commercial and Medicare plans. The solution is supported by clinical studies showing symptom improvement over time. Bausch Lomb operates in the healthcare sector, specifically targeting ophthalmic conditions with innovative treatments.
- SectorsHealthcare
- Website category Health · Pharmacy
- Phone•••• ••••
- Website xiidra.com
- Social LinkedIn X Facebook Instagram YouTube
- Acquired by Bausch & Lomb (Jun 2023)
- Legal Name Bausch + Lomb
- InvestorsBausch & Lomb
& 1 more
- Acquired by
Products & Services of Xiidra
Xiidra offers a comprehensive portfolio of products and services, including Xiidra.
Xiidra is used for treating dry eye symptoms.
Apps and channels of Xiidra
its YouTube channel Bausch + Lomb has 10.2K subscribers and 20 videos.
Videos from Xiidra
The most watched videos on Xiidra's YouTube channel, Bausch + Lomb (10.2K subscribers). Click a video to play it here.
More on Bausch + Lomb.
Investors in Xiidra
Xiidra has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Bausch & Lomb and Novartis.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Ophthalmic pharmaceuticals and instruments are developed for eye care. | 1853 | bausch.com | Bridgewater, United States | |
R&D focused on manufacturing of drugs for multiple therapeutic areas | 1996 | novartis.com | Basel, Switzerland |
Investor details for Xiidra
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Xiidra
3 dated milestones of Xiidra across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Xiidra is founded.
- Exit Acquired by Novartis.
- Exit Acquired by Bausch & Lomb.
Web traffic of Xiidra
The website of Xiidra (xiidra.com) receives about 45.5K visits a month and ranks #719,222 among all websites worldwide, #1,310 in Pharmacy.
- Monthly visits45.5K
▼ 9.7% vs previous month
- Unique visitors36.1K
per month
- Global rank#719,222
among all websites
- Category rank#1,310
Health · Pharmacy
- Bounce rate74%
- Pages per visit1.4
- Average visit30 sec
- DevicesDesktop 20% · Mobile 80%
Websites whose visitors overlap most with Xiidra. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
xiidra-ecp.com | xiidra-ecp.com | 100% | – | #136,284 | – |
rxpharmacycoupons.com | rxpharmacycoupons.com | 84% | – | #1,244,194 | – |
zyrtec.com | zyrtec.com | 74% | – | #408,931 | – |
savehealth.com | savehealth.com | 71% | – | #555,450 | – |
miebo-ecp.com | miebo-ecp.com | 68% | – | #194,541 | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 8 similar websites and full traffic analytics for Xiidra
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 8 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Traditional Health & Nutrition
10 companies that operate in the same segment as Xiidra (Traditional Health & Nutrition), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Manufacturer of generics formulations | 2002 | Bridgewater, New Jersey, United States | – | USD 3.02 B | 8,300 | |
Biosimilar therapeutics are developed for oncology and autoimmune diseases. | 2010 | Redwood City, California, United States | USD 143.62 M | USD 42.17 M | 228 | |
Oral solid drug delivery systems are manufactured and developed. | 1985 | Mumbai, Maharashtra, India | USD 42.49 M | USD 89.42 M | 962 | |
Ophthalmic pharmaceuticals and instruments are developed for eye care. | 1853 | Bridgewater, New Jersey, United States | – | USD 5.1 B | 13,500 | |
Generic pharmaceuticals are manufactured by Teva Pharmaceuticals. | 1901 | Petah Tikva, Central District, Israel | USD 500 M | USD 18.74 B | 51,792 | |
Generic, semi-solid, and liquid dosage forms are manufactured. | 1990 | Bengaluru, Karnataka, India | – | USD 508.93 M | 5,180 | |
Pharmaceutical products are developed and marketed globally. | 2009 | Montville, New Jersey, United States | USD 155.92 M | – | – | |
Specialty generic pharmaceuticals and APIs are manufactured and marketed. | 1983 | Mumbai, Maharashtra, India | – | USD 6.21 B | 25,870 | |
Pharmaceutical company engaged in developing, manufacturing, and marketing a diverse range of pharmaceutical formulations | 1991 | Delhi, Delhi, India | USD 367.2 M | USD 1.52 B | 21,320 | |
Generics, biosimilars, APIs, and vaccines are manufactured by Wockhardt. | 1967 | Mumbai, Maharashtra, India | – | USD 353.53 M | 3,410 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Xiidra
Xiidra was founded in 2013.
Xiidra, managed by Bausch Lomb, is focused on providing prescription eye drops for treating signs and symptoms of dry eye disease. The product is developed to address inflammation, a root cause of dry eye, offering relief in as little as two weeks with continued use. It is distributed across the United States with extensive insurance coverage for both commercial and Medicare plans. The solution is supported by clinical studies showing symptom improvement over time. Bausch Lomb operates in the healthcare sector, specifically targeting ophthalmic conditions with innovative treatments.
Xiidra offers Xiidra.
Xiidra has 2 investors. Key investors include Bausch & Lomb, and Novartis.
Xiidra operates through Bausch + Lomb.
Yes. Xiidra was acquired by Bausch & Lomb in June 2023.